Measuring clinical progression in MCI and pre-MCI populations: enrichment and optimizing clinical outcomes over time

Recent biomarker research has improved the identification of individuals with very early stages of Alzheimer's disease (AD) and has demonstrated that biomarkers are sensitive for measuring progression in the pre-dementia or mild cognitive impairment (MCI) stage and even pre-symptomatic or pre-M...

Descripción completa

Detalles Bibliográficos
Autor principal: Hendrix, Suzanne B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3506938/
https://www.ncbi.nlm.nih.gov/pubmed/22805433
http://dx.doi.org/10.1186/alzrt127

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3506938/
https://www.ncbi.nlm.nih.gov/pubmed/22805433
http://dx.doi.org/10.1186/alzrt127

Ejemplares similares